https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Axsome_Therapeutics%2C_Inc. 2026-04-07T14:21:27Z Istoricul versiunilor pentru această pagină din wiki MediaWiki 1.39.2 https://wiki.tradeville.ro/index.php?title=Axsome_Therapeutics,_Inc.&diff=447409&oldid=prev 2024-09-29T10:48:51Z

<p>The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).</p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="ro"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Versiunea anterioară</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Versiunea de la data 29 septembrie 2024 13:48</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l2">Linia 2:</td> <td colspan="2" class="diff-lineno">Linia 2:</td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Descriere companie==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Descriere companie==</div></td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Axsome Therapeutics, Inc. (www.axsome.com) is a biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders. The Company's core CNS portfolio includes five product candidates, which includes AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is an oral N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity for the treatment of major depressive disorder (MDD). AXS-07 is an oral multi-mechanistic medicine for the acute treatment of migraine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-09 is an oral NMDA receptor antagonist with multimodal activity consisting of esbupropion and dextromethorphan for the treatment of CNS disorders. AXS-12, reboxetine, is an oral medicine in development for the treatment of narcolepsy. AXS-14, esreboxetine is an oral medicine in development for the treatment of fibromyalgia.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Axsome Therapeutics, Inc. (www.axsome.com) is a biopharmaceutical company. The Company is engaged in developing therapies for the management of <ins style="font-weight: bold; text-decoration: none;">[[CENTRAL|</ins>central<ins style="font-weight: bold; text-decoration: none;">]] </ins>nervous system (CNS) disorders. The Company's core CNS portfolio includes five product candidates, which includes AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is an oral N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity for the treatment of major depressive disorder (MDD). AXS-07 is an oral multi-mechanistic medicine for the acute treatment of migraine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-09 is an oral NMDA receptor antagonist with multimodal activity consisting of esbupropion and dextromethorphan for the treatment of CNS disorders. AXS-12, reboxetine, is an oral medicine in development for the treatment of narcolepsy. AXS-14, esreboxetine is an oral medicine in development for the treatment of fibromyalgia.</div></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Grafic actiuni companie==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Grafic actiuni companie==</div></td></tr> <!-- diff cache key tradeville_wiki:diff::1.12:old-408431:rev-447409 --> </table>

127.0.0.1 https://wiki.tradeville.ro/index.php?title=Axsome_Therapeutics,_Inc.&diff=408431&oldid=prev 2024-09-18T13:40:50Z

<p>Pagină nouă: Pagina dedicata companiei Axsome Therapeutics, Inc. listata cu simbolul US.AXSM ==Descriere companie== Axsome Therapeutics, Inc. (www.axsome.com) is a biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders. The Company&#039;s core CNS portfolio includes five product candidates, which includes AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is an oral N-methyl-D-aspartate (NMDA) receptor antagonist...</p> <p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Axsome Therapeutics, Inc. listata cu simbolul US.AXSM<br /> <br /> ==Descriere companie==<br /> Axsome Therapeutics, Inc. (www.axsome.com) is a biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders. The Company's core CNS portfolio includes five product candidates, which includes AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is an oral N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity for the treatment of major depressive disorder (MDD). AXS-07 is an oral multi-mechanistic medicine for the acute treatment of migraine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-09 is an oral NMDA receptor antagonist with multimodal activity consisting of esbupropion and dextromethorphan for the treatment of CNS disorders. AXS-12, reboxetine, is an oral medicine in development for the treatment of narcolepsy. AXS-14, esreboxetine is an oral medicine in development for the treatment of fibromyalgia.<br /> <br /> ==Grafic actiuni companie==<br /> &lt;iframe key=&quot;tradeville&quot; path=&quot;graficSimbol/US.AXSM&quot; /&gt;<br /> <br /> ==Ultimele stiri despre Axsome Therapeutics, Inc. (US.AXSM)==<br /> &lt;dynamicpagelist&gt;<br /> category=US.AXSM<br /> count=10<br /> order=descending<br /> addfirstcategorydate=false<br /> &lt;/dynamicpagelist&gt;<br /> <br /> [[Categorie:US.AXSM]][[Categorie:Stiri despre companii]]</div>

Admin